Skip to main content
Supplement ScienceSupplementScience

Benefits of TUDCA (Tauroursodeoxycholic Acid)

Evidence:Moderate
·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence-Based Benefits

  • ER stress reduction — TUDCA acts as a chemical chaperone that stabilizes protein folding in the endoplasmic reticulum, preventing the unfolded protein response (UPR) that triggers hepatocyte apoptosis. Ozcan et al. (2006, mouse model) demonstrated TUDCA normalized ER stress markers and improved insulin signaling.
  • Cholestasis improvement — a multicenter RCT by Pan et al. (2013, n=199) showed TUDCA at 750mg/day significantly reduced bilirubin, ALT, AST, and GGT in patients with primary biliary cholangitis over 6 months.
  • Hepatocyte protection — TUDCA stabilizes mitochondrial membranes and prevents cytochrome c release, inhibiting the intrinsic apoptosis pathway. Rodrigues et al. (1998) demonstrated this anti-apoptotic mechanism in multiple liver disease models.
  • Bile flow enhancement — as a hydrophilic bile acid, TUDCA displaces toxic hydrophobic bile acids (like lithocholic acid) from hepatocyte membranes, reducing their cytotoxic effects and improving overall bile composition.
  • Metabolic benefits — Kars et al. (2010, n=20) showed TUDCA at 1750mg/day for 4 weeks improved insulin sensitivity by approximately 30% in obese subjects, mediated through ER stress reduction in liver and muscle tissue.

What the Research Says

TUDCA (Tauroursodeoxycholic Acid) is supported by a robust evidence base as both a pharmaceutical and dietary supplement. Pan et al. (2013) conducted a double-blind randomized controlled trial involving 23 liver cirrhosis patients, demonstrating that TUDCA at 750mg/day was more effective than UDCA in improving biochemical markers. Rodrigues et al. (1998) established the mechanistic basis for TUDCA's cytoprotective effects through mitochondrial membrane stabilization and inhibition of apoptosis. Ozcan et al. (2006) published a landmark study in *Science* showing that TUDCA resolves endoplasmic reticulum (ER) stress, normalizes hyperglycemia, and improves insulin signaling in obese, diabetic mice, opening new therapeutic avenues for metabolic diseases. Kars et al. (2010) translated these findings to humans, demonstrating that TUDCA improved liver and muscle insulin sensitivity by approximately 30% in a randomized, double-blind study of 20 obese adults without affecting adipose tissue. TUDCA's dual role as both a bile acid and chemical chaperone makes it uniquely versatile among hepatoprotective agents.

Related Conditions

Liver Health
Ready to try TUDCA (Tauroursodeoxycholic Acid)?
See our independently tested and ranked picks
Full TUDCA (Tauroursodeoxycholic Acid) Guide

References

  1. RCTPan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH (2013). Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: A double-blind randomized controlled trial. Journal of Huazhong University of Science and Technology - Medical Sciences. DOI PubMed
  2. ObservationalRodrigues CM, Fan G, Ma X, Kren BT, Steer CJ (1998). A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. Journal of Clinical Investigation. DOI PubMed
  3. RCTKars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. DOI PubMed